CAR-T EXOSOME AND EXO-ACE DATA PUBLISHED IN PEER REVIEWED JOURNAL
INOVIQ Ltd (ASX: IIQ)
· INOVIQ’s proprietary EXO-ACE platform for scalable CAR-exosome production platform published in Journal of Visualized Experiments (JoVE)
· EGFR- and HER2-targeted CAR-T-exosomes demonstrated potent in-vitro cancer-killing activity in breast and myeloid leukemia cell lines
· EXO-ACE validated for large-scale production of CAR-EVs, supporting preclinical development
INOVIQ Limited (ASX: IIQ) ("INOVIQ" or "the Company") is pleased to announce the publication of proof-of-concept (PoC) data demonstrating the in vitro cancer-killing efficacy of its engineered CAR-T-exosomes and the scalability of its proprietary EXO-ACE manufacturing platform. The peer-reviewed scientific paper, titled “Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy”, has been published in the Journal of Visualized Experiments (JoVE; link here).
The paper reports data from a previous study (ASX: 3 June 2024)[i] that INOVIQ’s CAR-T exosomes exhibit strong cytotoxic activity against breast and blood cancer cell lines. It also validates the EXO-ACE platform as a scalable, automated system for high-throughput production and analysis of CAR exosomes. EXO-ACE has been successfully applied to both CAR-NK and CAR-T exosomes across haematological and solid tumour models, demonstrating its versatility and readiness for therapeutic development.
CSO Prof Greg Rice said: “This publication validates the scientific rigour and therapeutic potential of our CAR-exosome platform across both haematological and solid tumours. Our proprietary EXO-ACE manufacturing process enables scalable production of engineered exosomes with potential safety, efficacy and cost advantages over autologous cell therapies.”
CEO Dr Leearne Hinch stated: “Our CAR-exosome therapies have the potential to transform cancer treatment with a cell-free approach to target and destroy solid tumours. We expect to report in vivo efficacy data for our CAR-NK-exosomes in a triple-negative breast cancer animal model by December 2025.”
Authorised for release by Company Secretary, Mark Edwards.
[i] Study results were previously reported as a poster presentation at the International Society for Stem Cell Research, 2-4 October 2024 entitled “CAR-Extracellular Vesicles: A Promising alternative to cell-based therapies”. This publication reports the detailed data presented and methods in the poster presentation and also the ASX announcement on 3 June 2024.
About us:
ABOUT INOVIQ LTD
INOVIQ Ltd (ASX: IIQ) is a leader in exosome technology advancing next-generation diagnostics and therapeutics that transform cancer care. Our product portfolio includes commercial-stage exosome isolation products, clinical-stage diagnostics for ovarian and breast cancers, and a cutting-edge preclinical CAR-exosome therapeutic program for solid tumours. INOVIQ is shaping the future of cancer detection and treatment to improve patient outcomes. For more information on INOVIQ, visit www.inoviq.com.
Contact details:
Dr Leearne Hinch
Chief Executive Officer
M +61 400 414 416
- Images
-
Download
15723_INOVIQ_RGB (4).png
INOVIQ Ltd (ASX: IIQ)
